1 | abstract | 3,748 |
2 | hereafter | 116 |
3 | triticum | 87 |
4 | vaccinium | 55 |
5 | macaca | 34 |
6 | henceforth | 28 |
7 | 2-ltr | 22 |
8 | hereinafter | 20 |
9 | papio | 17 |
10 | n-terminally | 10 |
11 | rs3 | 10 |
12 | c-terminally | 9 |
13 | states-short | 8 |
14 | 1=not | 6 |
15 | afterlife | 5 |
16 | hagloidea | 5 |
17 | rw3 | 5 |
18 | sabcs | 5 |
19 | vc1 | 5 |
20 | central- | 4 |
21 | mscis | 4 |
22 | pnq | 4 |
23 | t-32 | 4 |
24 | arcane | 3 |
25 | auditory/visual | 3 |
26 | controllo | 3 |
27 | higher-impact | 3 |
28 | lacerta | 3 |
29 | ldcvs | 3 |
30 | ncdr | 3 |
31 | thecochranelibrary | 3 |
32 | uspto | 3 |
33 | 3,670 | 2 |
34 | anticarsia | 2 |
35 | biovaxid | 2 |
36 | clinician-derived | 2 |
37 | crt-implantable | 2 |
38 | galaxea | 2 |
39 | hr19 | 2 |
40 | lfcn | 2 |
41 | lvedm | 2 |
42 | preventive-therapeutic | 2 |
43 | programme-implantable | 2 |
44 | toxascaris | 2 |
45 | verband | 2 |
46 | wrap-up | 2 |
47 | 'infraclavicular | 1 |
48 | 'regulatory | 1 |
49 | -33.8±3.9 | 1 |
50 | -impact | 1 |
51 | 0.32-32.0 | 1 |
52 | 100-120g | 1 |
53 | 2.3±1.6 | 1 |
54 | 2pn/ | 1 |
55 | 3.6°-8.7° | 1 |
56 | 37-atom | 1 |
57 | 39.3+/-0.2/40.0+/-0.2 | 1 |
58 | 4.48°c | 1 |
59 | 66,200 | 1 |
60 | =3.0mg/dl | 1 |
61 | =abs-b | 1 |
62 | acid-terminal | 1 |
63 | ampelomyces | 1 |
64 | axial-rich | 1 |
65 | bdi-short | 1 |
66 | caeasily | 1 |
67 | candelabra | 1 |
68 | carboxyl-terminally | 1 |
69 | cardopatium | 1 |
70 | control=assessment | 1 |
71 | cooperation-related | 1 |
72 | counselling/peer | 1 |
73 | crt/implantable | 1 |
74 | diphtheria-toxoid-tetanus-toxoid | 1 |
75 | diptera.the | 1 |
76 | eosinophil-dominant | 1 |
77 | er-beta+ | 1 |
78 | fitvibe | 1 |
79 | flexopecten | 1 |
80 | gate-induced | 1 |
81 | implantatable | 1 |
82 | implicative | 1 |
83 | ingredient/dosage | 1 |
84 | interview-short | 1 |
85 | iupac | 1 |
86 | jlg-2 | 1 |
87 | jm-103 | 1 |
88 | lario | 1 |
89 | lifepak® | 1 |
90 | lived-experience | 1 |
91 | lps-insensitive | 1 |
92 | magneto-optic | 1 |
93 | mcpdai-were | 1 |
94 | methanol-acetonitrile-trifluoroacetic | 1 |
95 | miosis.our | 1 |
96 | mirounga | 1 |
97 | mpr/ | 1 |
98 | mz-29 | 1 |
99 | neonatus | 1 |
100 | non-science | 1 |
101 | nonphosphorylative | 1 |
102 | p-300 | 1 |
103 | p.h195fsx28 | 1 |
104 | p.q2824x | 1 |
105 | pessimistic/suicidal | 1 |
106 | pseudo-hexa-gonal | 1 |
107 | qpgs- | 1 |
108 | questionarie | 1 |
109 | questionnaire-taiwan | 1 |
110 | reactivation.the | 1 |
111 | review×primary | 1 |
112 | rna-optimized | 1 |
113 | ron-strategic | 1 |
114 | rs4810485 | 1 |
115 | satisfactory/not | 1 |
116 | sbar-based | 1 |
117 | slitone | 1 |
118 | slow/fast | 1 |
119 | sollievo | 1 |
120 | strata.the | 1 |
121 | tetrao | 1 |
122 | toyohari | 1 |
123 | vaccinum | 1 |
124 | vitatron | 1 |
125 | worst-best | 1 |
126 | wsj/medical | 1 |
127 | •major | 1 |
1 | 'infraclavicular | 1 |
2 | 'regulatory | 1 |
3 | -33.8±3.9 | 1 |
4 | -impact | 1 |
5 | 0.32-32.0 | 1 |
6 | 100-120g | 1 |
7 | 1=not | 6 |
8 | 2-ltr | 22 |
9 | 2.3±1.6 | 1 |
10 | 2pn/ | 1 |
11 | 3,670 | 2 |
12 | 3.6°-8.7° | 1 |
13 | 37-atom | 1 |
14 | 39.3+/-0.2/40.0+/-0.2 | 1 |
15 | 4.48°c | 1 |
16 | 66,200 | 1 |
17 | =3.0mg/dl | 1 |
18 | =abs-b | 1 |
19 | abstract | 3,748 |
20 | acid-terminal | 1 |
21 | afterlife | 5 |
22 | ampelomyces | 1 |
23 | anticarsia | 2 |
24 | arcane | 3 |
25 | auditory/visual | 3 |
26 | axial-rich | 1 |
27 | bdi-short | 1 |
28 | biovaxid | 2 |
29 | c-terminally | 9 |
30 | caeasily | 1 |
31 | candelabra | 1 |
32 | carboxyl-terminally | 1 |
33 | cardopatium | 1 |
34 | central- | 4 |
35 | clinician-derived | 2 |
36 | control=assessment | 1 |
37 | controllo | 3 |
38 | cooperation-related | 1 |
39 | counselling/peer | 1 |
40 | crt-implantable | 2 |
41 | crt/implantable | 1 |
42 | diphtheria-toxoid-tetanus-toxoid | 1 |
43 | diptera.the | 1 |
44 | eosinophil-dominant | 1 |
45 | er-beta+ | 1 |
46 | fitvibe | 1 |
47 | flexopecten | 1 |
48 | galaxea | 2 |
49 | gate-induced | 1 |
50 | hagloidea | 5 |
51 | henceforth | 28 |
52 | hereafter | 116 |
53 | hereinafter | 20 |
54 | higher-impact | 3 |
55 | hr19 | 2 |
56 | implantatable | 1 |
57 | implicative | 1 |
58 | ingredient/dosage | 1 |
59 | interview-short | 1 |
60 | iupac | 1 |
61 | jlg-2 | 1 |
62 | jm-103 | 1 |
63 | lacerta | 3 |
64 | lario | 1 |
65 | ldcvs | 3 |
66 | lfcn | 2 |
67 | lifepak® | 1 |
68 | lived-experience | 1 |
69 | lps-insensitive | 1 |
70 | lvedm | 2 |
71 | macaca | 34 |
72 | magneto-optic | 1 |
73 | mcpdai-were | 1 |
74 | methanol-acetonitrile-trifluoroacetic | 1 |
75 | miosis.our | 1 |
76 | mirounga | 1 |
77 | mpr/ | 1 |
78 | mscis | 4 |
79 | mz-29 | 1 |
80 | n-terminally | 10 |
81 | ncdr | 3 |
82 | neonatus | 1 |
83 | non-science | 1 |
84 | nonphosphorylative | 1 |
85 | p-300 | 1 |
86 | p.h195fsx28 | 1 |
87 | p.q2824x | 1 |
88 | papio | 17 |
89 | pessimistic/suicidal | 1 |
90 | pnq | 4 |
91 | preventive-therapeutic | 2 |
92 | programme-implantable | 2 |
93 | pseudo-hexa-gonal | 1 |
94 | qpgs- | 1 |
95 | questionarie | 1 |
96 | questionnaire-taiwan | 1 |
97 | reactivation.the | 1 |
98 | review×primary | 1 |
99 | rna-optimized | 1 |
100 | ron-strategic | 1 |
101 | rs3 | 10 |
102 | rs4810485 | 1 |
103 | rw3 | 5 |
104 | sabcs | 5 |
105 | satisfactory/not | 1 |
106 | sbar-based | 1 |
107 | slitone | 1 |
108 | slow/fast | 1 |
109 | sollievo | 1 |
110 | states-short | 8 |
111 | strata.the | 1 |
112 | t-32 | 4 |
113 | tetrao | 1 |
114 | thecochranelibrary | 3 |
115 | toxascaris | 2 |
116 | toyohari | 1 |
117 | triticum | 87 |
118 | uspto | 3 |
119 | vaccinium | 55 |
120 | vaccinum | 1 |
121 | vc1 | 5 |
122 | verband | 2 |
123 | vitatron | 1 |
124 | worst-best | 1 |
125 | wrap-up | 2 |
126 | wsj/medical | 1 |
127 | •major | 1 |
1 | er-beta+ | 1 |
2 | central- | 4 |
3 | qpgs- | 1 |
4 | 2pn/ | 1 |
5 | mpr/ | 1 |
6 | 0.32-32.0 | 1 |
7 | 66,200 | 1 |
8 | p-300 | 1 |
9 | 3,670 | 2 |
10 | vc1 | 5 |
11 | jlg-2 | 1 |
12 | 39.3+/-0.2/40.0+/-0.2 | 1 |
13 | t-32 | 4 |
14 | jm-103 | 1 |
15 | rs3 | 10 |
16 | rw3 | 5 |
17 | rs4810485 | 1 |
18 | 2.3±1.6 | 1 |
19 | p.h195fsx28 | 1 |
20 | -33.8±3.9 | 1 |
21 | hr19 | 2 |
22 | mz-29 | 1 |
23 | macaca | 34 |
24 | hagloidea | 5 |
25 | galaxea | 2 |
26 | mirounga | 1 |
27 | anticarsia | 2 |
28 | candelabra | 1 |
29 | lacerta | 3 |
30 | =abs-b | 1 |
31 | iupac | 1 |
32 | ron-strategic | 1 |
33 | methanol-acetonitrile-trifluoroacetic | 1 |
34 | magneto-optic | 1 |
35 | preventive-therapeutic | 2 |
36 | 4.48°c | 1 |
37 | gate-induced | 1 |
38 | sbar-based | 1 |
39 | cooperation-related | 1 |
40 | clinician-derived | 2 |
41 | rna-optimized | 1 |
42 | diphtheria-toxoid-tetanus-toxoid | 1 |
43 | biovaxid | 2 |
44 | verband | 2 |
45 | fitvibe | 1 |
46 | non-science | 1 |
47 | lived-experience | 1 |
48 | afterlife | 5 |
49 | ingredient/dosage | 1 |
50 | diptera.the | 1 |
51 | strata.the | 1 |
52 | reactivation.the | 1 |
53 | questionarie | 1 |
54 | implantatable | 1 |
55 | programme-implantable | 2 |
56 | crt-implantable | 2 |
57 | crt/implantable | 1 |
58 | arcane | 3 |
59 | slitone | 1 |
60 | mcpdai-were | 1 |
61 | implicative | 1 |
62 | nonphosphorylative | 1 |
63 | lps-insensitive | 1 |
64 | 100-120g | 1 |
65 | axial-rich | 1 |
66 | henceforth | 28 |
67 | toyohari | 1 |
68 | wsj/medical | 1 |
69 | pessimistic/suicidal | 1 |
70 | acid-terminal | 1 |
71 | pseudo-hexa-gonal | 1 |
72 | auditory/visual | 3 |
73 | =3.0mg/dl | 1 |
74 | lvedm | 2 |
75 | 37-atom | 1 |
76 | triticum | 87 |
77 | vaccinium | 55 |
78 | cardopatium | 1 |
79 | vaccinum | 1 |
80 | questionnaire-taiwan | 1 |
81 | lfcn | 2 |
82 | flexopecten | 1 |
83 | vitatron | 1 |
84 | tetrao | 1 |
85 | papio | 17 |
86 | lario | 1 |
87 | controllo | 3 |
88 | uspto | 3 |
89 | sollievo | 1 |
90 | wrap-up | 2 |
91 | pnq | 4 |
92 | 'infraclavicular | 1 |
93 | ncdr | 3 |
94 | counselling/peer | 1 |
95 | hereafter | 116 |
96 | hereinafter | 20 |
97 | •major | 1 |
98 | 2-ltr | 22 |
99 | miosis.our | 1 |
100 | sabcs | 5 |
101 | ampelomyces | 1 |
102 | mscis | 4 |
103 | toxascaris | 2 |
104 | neonatus | 1 |
105 | ldcvs | 3 |
106 | -impact | 1 |
107 | higher-impact | 3 |
108 | abstract | 3,748 |
109 | eosinophil-dominant | 1 |
110 | control=assessment | 1 |
111 | satisfactory/not | 1 |
112 | 1=not | 6 |
113 | bdi-short | 1 |
114 | states-short | 8 |
115 | interview-short | 1 |
116 | slow/fast | 1 |
117 | worst-best | 1 |
118 | p.q2824x | 1 |
119 | caeasily | 1 |
120 | c-terminally | 9 |
121 | carboxyl-terminally | 1 |
122 | n-terminally | 10 |
123 | review×primary | 1 |
124 | thecochranelibrary | 3 |
125 | 'regulatory | 1 |
126 | lifepak® | 1 |
127 | 3.6°-8.7° | 1 |